Interaction Between Vascular Factors and the APOE ε4 Allele in Predicting Rate of Progression in Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Vascular factors have been shown to affect the rate of Alzheimer's disease (AD) progression. However, the effect of the APOE ε4 allele on rate of progression has been ambiguous. Little research to date has examined an interaction between vascular factors and the APOE ε4 allele in predicting decline among AD patients. 216 participants with incident AD from a population of elderly persons in Cache County, Utah, were followed for a mean of 3.3 years and 4.2 follow-up visits. A history of vascular risk factors and conditions and anti-hypertensive use was assessed at the diagnostic visit. Linear mixed effects models tested interactions between the vascular factors, APOE ε4, and time as predictors of clinical progression on the Mini-Mental State Exam (MMSE) and Clinical Dementia Rating-Sum of Boxes (CDR-SB). Multiple comparisons were corrected using the Holm-Bonferroni method. There was a 3-way interaction between stroke, APOE ε4 and time in predicting MMSE decline (LR χ² = 10.32, 2 df, p = 0.006). For the CDR-SB, there were 3-way interactions between the APOE ε4, time and either myocardial infarction (LR χ² = 17.83, 2 df, p = 0.0001) or stroke (LR χ² = 11.48, 2 df, p = 0.003. Results suggest a complex relationship between the APOE ε4 and vascular factors in predicting cognitive and functional progression. Among individuals with a history of stroke or myocardial infarction at baseline, progression of AD is influenced by APOE ε4 carrier status and varies by time after AD diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Probability of stroke: a risk profile from the Framingham Study.
Wolf, P. A., D'Agostino, R. B., Belanger, A. J., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.3.312 · Cited by 1,782 · cited 1×
“This index was similar to the Framingham Stroke Risk Profile [33] but incorporated more self-reported data and was therefore closer to methods of the present study.”
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747 · cited 1×
“3–times more likely to develop AD, while the risk for homozygous carriers is even higher [2, 3].”
APOE -ε4 count predicts age when prevalence of AD increases, then declines: The Cache County Study
Breitner, J. C. S., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., Norton, M. C., Tschanz, J. T., Plassman, B. L., Meyer, M. R., Skoog, I., et al. (1999) · Neurology · doi:10.1212/wnl.53.2.321 · Cited by 397
Self-citationAPOE alleles predict the rate of cognitive decline in Alzheimer disease: A nonlinear model
Martins, C. A. R., Oulhaj, A., de Jager, C. A., & Williams, J. H. (2005) · Neurology · doi:10.1212/01.wnl.0000188871.74093.12 · Cited by 205
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152
Frisoni, G. B., Govoni, S., Geroldi, C., Bianchetti, A., Calabresi, L., Franceschini, G., & Trabucchi, M. (1995) · Annals of Neurology · doi:10.1002/ana.410370509 · Cited by 149
Association of APOE genotype with carotid atherosclerosis in men and women
Elosua, R., Ordovas, J. M., Cupples, L. A., Fox, C. S., Polak, J. F., Wolf, P. A., D’Agostino, R. A., & O’Donnell, C. J. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400114-jlr200 · Cited by 101 · cited 1×
“Carriers of an 4 allele are also at an increased risk of vascular disease including myocardial infarction [4], carotid atherosclerosis [5], and hypertension [6].”
Cited by
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Combining modifiable risk factors and risk of dementia: a systematic review and meta-analysis
Peters, R., Booth, A., Rockwood, K., Peters, J., D’Este, C., & Anstey, K. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022846 · Cited by 255
Heart disease as a risk factor for dementia
Hakim, A., Ng, & Turek (2013) · Clinical Epidemiology · doi:10.2147/clep.s30621 · Cited by 229
“107,108”
Anti-inflammatories in Alzheimer’s disease—potential therapy or spurious correlate?
Rivers-Auty, J., Mather, A. E., Peters, R., Lawrence, C. B., & Brough, D. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa109 · Cited by 130
Sherva, R., Gross, A., Mukherjee, S., Koesterer, R., Amouyel, P., Bellenguez, C., Dufouil, C., Bennett, D. A., Chibnik, L., Cruchaga, C., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12106 · Cited by 54
Self-citationGilbert, M., Snyder, C., Corcoran, C., Norton, M. C., Lyketsos, C. G., & Tschanz, J. T. (2014) · International Psychogeriatrics · doi:10.1017/s1041610214000842 · Cited by 48
“Several health-related conditions have been examined as predictors of decline in AD, including but not limited to cardiovascular (Helzner et al., 2009) or cerebrovascular disease (Helzner et al., 2009; Mielke et al., 2011).”
BackgroundSelf-citation
Metadata
- Authors
- Mielke, M. M., Leoutsakos, J.-M., Tschanz, J. T., Green, R. C., Tripodis, Y., Corcoran, C. D., Norton, M. C., & Lyketsos, C. G.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2011-08-26
- Volume
- 26
- Issue
- 1
- Pages
- 127-134
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W124557036
- Cited by
- 40
- References
- 9
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.